A promising obesity and diabetes drug stumbles in Alzheimer's trials, rattling markets. Did investors overreact, or is this a ...

The slump has virtually wiped out several years of stellar gains that came after Novo’s Wegovy drug was approved as a ...

Novo Nordisk stock plunges 42% so far in 2025 as GLP-1 competition, price cuts, guidance trims and restructuring plans cloud ...

Explore Alnylam Pharmaceuticals' outlook as TTR franchise growth, competitive pressures, and valuation create a potential ...

Novo Nordisk (NVO) remains a strong buy in the weight loss/diabetes market despite challenges. Read here for an investment analysis.

Novo Nordisk said on Monday that two late-stage trials testing an older oral version of its semaglutide drug failed to meet their main goal.

Investing.com -- Novo Nordisk’s valuation remains under pressure as competitive threats intensify and analysts at Jefferies ...

Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit weight-loss drugs didn't slow the progress of Alzheimer's disease. Novo ...

Novo Nordisk ( (NVO)) has provided an update. On November 14, 2025, Novo Nordisk A/S held an Extraordinary General Meeting to elect new members to its Board of Directors. The meeting resulted in ...

Novo Nordisk NVO shares have plunged 10.2% over three months as regulatory setbacks, a 2025 guidance cut, and softer demand for its blockbuster semaglutide-based (GLP-1) drugs, Ozempic (for type II ...

Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...